NATURAL-HISTORY OF CLINICALLY LOCALIZED PROSTATE-CANCER

被引：8

作者：

BARRY, MJ

机构：

[1] Medical Practices Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

来源：

SEMINARS IN SURGICAL ONCOLOGY | 1995年 / 11卷 / 01期

关键词：

PROSTATIC NEOPLASMS; PROGNOSIS; MORTALITY; RISK FACTORS; EPIDEMIOLOGY;

D O I：

10.1002/ssu.2980110103

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The natural history of clinically localized prostate cancer is controversial. However, the data that is available suggests outcomes are good for men with well and moderately differentiated disease, but relatively poor for men with poorly differentiated cancer. For example, in one synthesis of individual-patient level data from six series, ten-year prostate cancer-specific mortality for men with well, moderate, and poorly differentiated disease was estimated at 13%, 13%, and 66%, respectively. Tumor grade is the dominant predictor of prognosis. Few studies report on risks of morbidity due to local cancer progression; the data available suggest this risk is relatively low. Cancer-specific mortality figures overestimate the impact of disease among older men with competing causes of mortality. Given the available data on prognosis of men with localized prostate cancer not treated for cure, clinical trials designed to measure the effectiveness of aggressive therapy will need to be large. (C) 1995 Wiley-Liss, Inc.

引用

页码：3 / 8

页数：6

共 27 条

[1]

Boring CC, Squires TS, Tong T, Montgomery S, Cancer statistics, 1994, CA Cancer J Clin, 44, pp. 7-26, (1994)

[2]

Boring CC, Squires TS, Tong T, Cancer statistics, 1992, CA Cancer J Clin, 42, pp. 19-38, (1992)

[3]

Lu-Yao GL, McLerran D, Wasson J, Et al., An assessment of radical prostatectomy: Time trends, geographic variation, and outcomes, JAMA, 269, pp. 2633-2636, (1993)

[4]

Lu-Yao G, Greenberg ER, Changes in prostate cancer incidence and treatment in USA, Lancet, 343, pp. 251-254, (1994)

[5]

Johansson JE, Adami HO, Andersson SO, Et al., High 10‐year survival rate in patients with early, untreated prostatic cancer, JAMA, 267, pp. 2191-2196, (1992)

[6]

Johansson JE, Watchful waiting for early stage prostate cancer, Urology, 43, pp. 138-142, (1994)

[7]

Adolfsson J, Carstensen J, Lowhagen T, Deferred treatment in clinically localised prostatic carcinoma, Brit J Urol, 69, pp. 183-187, (1992)

[8]

George NJ, Natural history of localised prostatic cancer managed by conservative therapy alone, Lancet, 1, pp. 494-497, (1988)

[9]

Blackard CE, Mellinger GT, Gleason DF, Treatment of stage 1 carcinoma of the prostate: a preliminary report, J Urol, 106, pp. 729-733, (1971)

[10]

Haapiainen R, Rannikko S, Makinen J, Alfthan O, T<sub>0</sub> carcinoma of the prostate: Influence of tumor extent and histologie grade on prognosis of untreated patients, Eur Urol, 12, pp. 16-20, (1986)

← 1 2 3 →